Hypercholesterolaemia and vascular dementia

被引:117
作者
Appleton, Jason P. [1 ]
Scutt, Polly [1 ]
Sprigg, Nikola [1 ]
Bath, Philip M. [1 ]
机构
[1] Univ Nottingham, Div Clin Neurosci, Stroke Trials Unit, Nottingham NG5 1PB, England
关键词
IDEAL CARDIOVASCULAR HEALTH; SMALL-VESSEL DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN-E GENOTYPE; WHITE-MATTER HYPERINTENSITIES; MODERATE ALZHEIMER-DISEASE; SERUM TOTAL CHOLESTEROL; CORONARY-HEART-DISEASE; LIPID-LOWERING AGENTS; AMYLOID-BETA PEPTIDE;
D O I
10.1042/CS20160382
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Vascular dementia (VaD) is the second commonest cause of dementia. Stroke is the leading cause of disability in adults in developed countries, the second major cause of dementia and the third commonest cause of death. Traditional vascular risk factors - diabetes, hypercholesterolaemia, hypertension and smoking - are implicated as risk factors for VaD. The associations between cholesterol and small vessel disease (SVD), stroke, cognitive impairment and subsequent dementia are complex and as yet not fully understood. Similarly, the effects of lipids and lipid-lowering therapy on preventing or treating dementia remain unclear; the few trials that have assessed lipid-lowering therapy for preventing (two trials) or treating (four trials) dementia found no evidence to support the use of lipid-lowering therapy for these indications. It is appropriate to treat those patients with vascular risk factors that meet criteria for lipid-lowering therapy for the primary and secondary prevention of cardiovascular and cerebrovascular events, and in line with current guidelines. Managing the individual patient in a holistic manner according to his or her own vascular risk profile is recommended. Although the paucity of randomized controlled evidence makes for challenging clinical decision making, it provides multiple opportunities for on-going and future research, as discussed here.
引用
收藏
页码:1561 / 1578
页数:18
相关论文
共 194 条
[1]   Statins in stroke prevention and carotid atherosclerosis -: Systematic review and up-to-date meta-analysis [J].
Amarenco, P ;
Labreuche, J ;
Lavallée, P ;
Touboul, PJ .
STROKE, 2004, 35 (12) :2902-2909
[2]   Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention [J].
Amarenco, Pierre ;
Labreuche, Julien .
LANCET NEUROLOGY, 2009, 8 (05) :453-463
[3]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[4]  
Amgen, 2017, AMG ANN REP EV SIGN, V2017
[5]   Clinical trials for preventing post stroke cognitive impairment [J].
Ankolekar, Sandeep ;
Geeganage, Chamila ;
Anderton, Peter ;
Hogg, Cheryl ;
Bath, Philip M. W. .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 299 (1-2) :168-174
[6]   Intracerebral hemorrhage [J].
Badjatia, N ;
Rosand, J .
NEUROLOGIST, 2005, 11 (06) :311-324
[7]   Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress [J].
Bae, JH ;
Bassenge, E ;
Kim, KB ;
Kim, YN ;
Kim, KS ;
Lee, HJ ;
Moon, KC ;
Lee, MS ;
Park, KY ;
Schwemmer, M .
ATHEROSCLEROSIS, 2001, 155 (02) :517-523
[8]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[9]   Pathology of Lacunar Ischemic Stroke in HumansuA Systematic Review [J].
Bailey, Emma L. ;
Smith, Colin ;
Sudlow, Cathie L. M. ;
Wardlaw, Joanna M. .
BRAIN PATHOLOGY, 2012, 22 (05) :583-591
[10]   Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women [J].
Bansal, Sandeep ;
Buring, Julie E. ;
Rifai, Nader ;
Mora, Samia ;
Sacks, Frank M. ;
Ridker, Paul M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (03) :309-316